Adicet Bio, Inc.
ACETNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$122.1M | −$127.6M | −$152.0M | −$72.6M | −$61.4M | −$39.2M |
| Net income | −$116.8M | −$117.1M | −$142.7M | −$69.8M | −$62.0M | −$36.7M |
| Total assets | $192.4M | $220.2M | $207.3M | $330.7M | $338.9M | $153.8M |
| Total liabilities | $33.1M | $33.6M | $37.1M | $38.4M | $35.8M | $44.0M |
| Equity | $159.2M | $186.6M | $170.2M | $292.3M | $303.1M | $109.8M |
| EPS (diluted) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 | — |
| Shares out. | 82.7M | 82.2M | 43.0M | 39.9M | 31.8M | 36.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −73.4%
- Return on assets
- −60.7%
- Return on capital (ROCE)
- −71.5%
- Liabilities / assets
- 17.2%
- Debt / equity
- 0.21×
- Book value / share
- $1.93
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -4.89distress
- Accruals / assets
- −11.2%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Woodline Partners LpPassive (13G)May 15, 2026
- Ra Capital Management, L.P.Passive (13G)Apr 13, 2026
- Orbimed Advisors LlcActivist (13D)Apr 10, 2026
- Tang Capital Management LlcPassive (13G)Feb 17, 2026
- Franklin Resources IncPassive (13G)Jan 29, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ra Capital Management, L.P.10% owner | Apr 27, 2026 | J | 250,000 | — |
| Ra Capital Management, L.P.10% owner | Feb 18, 2026 | Buy | 74,577 | $7.04 |
| Orbimed Advisors Llc10% owner | Apr 7, 2026 | Sell | 29,319 | $6.53 |
| Aftab BlakeOfficer — Chief Scientific Officer | Jan 24, 2026 | Tax withholding | 535 | $8.44 |
| Healey DonOfficer — Chief Technology Officer | Jan 24, 2026 | Tax withholding | 535 | $8.44 |
| Schor ChenOfficer — President & CEO | Jan 24, 2026 | Tax withholding | 1,755 | $8.44 |
| Harvey Brian NicholasOfficer — Chief Financial Officer | Jan 24, 2026 | Tax withholding | 546 | $8.44 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 587,837 | 5.7 | +6.2% |
| Apr 30, 2026 | 553,507 | 5.7 | -7.5% |
| Apr 15, 2026 | 598,458 | 3.2 | -8.8% |
| Mar 31, 2026 | 656,546 | 6.0 | +3.4% |
| Mar 13, 2026 | 634,967 | 5.9 | -0.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 13, 2026
- Unregistered equity saleApr 28, 2026
- Results of operationsMar 12, 2026
- Regulation FD disclosure · Other material eventJan 7, 2026
- Amended charter or bylaws · Other material eventDec 29, 2025
- Shareholder voteDec 19, 2025
- Results of operationsNov 5, 2025
- Delisting / listing-standard noticeOct 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-K/AMay 20, 2026
- SCHEDULE 13G/AMay 15, 2026
- S-8 POSMay 13, 2026
- 10-QMay 13, 2026
- 8-KMay 13, 2026
- 4Apr 29, 2026
- ARSApr 29, 2026
- DEFA14AApr 29, 2026
- DEF 14AApr 29, 2026
- 8-KApr 28, 2026
- SCHEDULE 13G/AApr 13, 2026
- 4Apr 13, 2026
- 3Apr 13, 2026
- SCHEDULE 13D/AApr 10, 2026
- 4Apr 9, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.